Beam Therapeutics Inc. (BEAM)

Market Closed

16 Oct, 08:00 PM

NASDAQ (NGS)

23. 47

-1.26

-5.095%

2.64B Market Cap

- P/E Ratio

- Div Yield

1.65M Volume

-5.38 Eps

$ 24.73

Previous Close

Investors:

+50

Analysts:

Add Transaction

Day Range

23.16 24.56

Year Range

20.23 38.26

Want to track BEAM and more in your Portfolio? 🎯

Get Started For Free

Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story

Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine company with a clear commercial bridge. BEAM's $1.2B cash position supports a runway into mid-2029, enabling pivotal programs in sickle cell disease (Risto-cel) and AATD (BEAM-302). Risto-cel targets process efficiency and efficacy in SCD, with a potential BLA submission by year-end 2026; BEAM-302 pursues accelerated approval in AATD.

Seekingalpha | 5 months ago

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.

Zacks | 5 months ago

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $1.24 per share a year ago.

Zacks | 5 months ago

3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.

Marketbeat | 5 months ago

BEAM Eyes Global Expansion of AATD Study After Strong Early Data

Beam Therapeutics reports promising phase I/II data for BEAM-302 in AATD, showing strong efficacy, tolerability and potential as a one-time curative treatment.

Zacks | 6 months ago

Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

Seekingalpha | 6 months ago

Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?

BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.

Zacks | 7 months ago

Beam Therapeutics: Great Potential, But Patience Is Needed

Beam Therapeutics Inc. is rated a Buy for its leadership in proprietary base-editing gene therapy, targeting significant unmet needs in hematology and liver diseases. BEAM's risto-cel shows superior efficacy in sickle cell disease, but commercial success hinges on overcoming conditioning protocol challenges and competing with Vertex/Crispr's head start. The liver-targeted BEAM-302 program demonstrates strong early clinical results and could establish a competitive moat, with pivotal data and BLA submission expected in 18–24 months.

Seekingalpha | 7 months ago